Description
Product Characteristics:
The proto oncogene c CBL was initially identified as the cellular homologue of v CBL oncogene that induces pre B cell lymphomas and myeloid leukemias in mice. In more recent studies CBL has been shown to be a negative regulator of tyrosine kinase signaling. The ubiquitin ligase activity of CBL leads to the degradation of tyrosine kinases, thus attenuating the signal of receptors. Targets of CBL include activated protein tyrosine kinases belonging to the Src and Syk/Zap 70 families. An additional mechanism to attenuate receptor signaling is thought to be achieved by CBL?s interaction with downstream targets of tyrosine kinases, such as PI 3K and Vav.
Subcellular location: Cytoplasm
Synonyms: C CBL Tyr731, CBL2 Tyr731, CBL2 Tyr731, p-CBL2 Tyr731, p-CBL2 Y731, C CBL, Cas-Br-M murine ecotropic retroviral transforming sequence, Casitas B lineage lymphoma proto oncogene, CBL 2,E3 ubiquitin protein ligase CBL, Oncogene CBL2, Proto oncogene c CBL, RGD1561386, RING finger protein 55, RNF55v Signal transduction protein CBL, 4732447J05Rik, CBL_HUMAN.
Target Information: This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Mar 2012]